Clinical implication of serum uric acid level in pegylated interferon and ribavirin combination therapy for chronic hepatitis C infection
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Combined treatment of pegylated interferon-α (PEG-IFN) and ribavirin (RBV) has long been accepted as the standard treatment for chronic hepatitis C virus (HCV) infection. Many predictive factors for treatment response have been identified. The aim of this study was to evaluate the efficacy and safety of combined PEG-IFN plus RBV and to examine the value of serum uric acid as a predictive factor in the treatment of chronic hepatitis C. Methods: A total of 74 patients chronically infected with HCV were enrolled between December 2004 and June 2009. Patients received subcutaneous PEG-IFN (α-2a: 180 μg once a week) in combination with RBV (1,000 to 1,200 mg daily depending on body weight). We evaluated treatment responses represented by early virologic response (EVR), end-of-treatment response (ETR), sustained virologic response (SVR), and relapse, as well as diverse adverse events. Various viral and host features were also assessed to clarify factors associated with treatment response. Results: During treatment, EVR was achieved in 26 patients (26/33, 78.8%) with HCV genotype 1. ETR and SVR were achieved in 59 (77.6%) and 56 patients (73.6%), respectively, across all genotypes. Genotype 2/3, lower HCV RNA, and lower uric acid were associated with higher SVR. Conclusions: The treatment response to combination therapy with PEG-IFN plus RBV was effective, especially in genotype 2/3. Uric acid might be useful as a predictive factor for response to therapy for chronic hepatitis.
Abstract
Background/Aims: Combined treatment of pegylated interferon-α (PEG-IFN) and ribavirin (RBV) has long been accepted as the standard treatment for chronic hepatitis C virus (HCV) infection. Many predictive factors for treatment response have been identified. The aim of this study was to evaluate the efficacy and safety of combined PEG-IFN plus RBV and to examine the value of serum uric acid as a predictive factor in the treatment of chronic hepatitis C. Methods: A total of 74 patients chronically infected with HCV were enrolled between December 2004 and June 2009. Patients received subcutaneous PEG-IFN (α-2a: 180 μg once a week) in combination with RBV (1,000 to 1,200 mg daily depending on body weight). We evaluated treatment responses represented by early virologic response (EVR), end-of-treatment response (ETR), sustained virologic response (SVR), and relapse, as well as diverse adverse events. Various viral and host features were also assessed to clarify factors associated with treatment response. Results: During treatment, EVR was achieved in 26 patients (26/33, 78.8%) with HCV genotype 1. ETR and SVR were achieved in 59 (77.6%) and 56 patients (73.6%), respectively, across all genotypes. Genotype 2/3, lower HCV RNA, and lower uric acid were associated with higher SVR. Conclusions: The treatment response to combination therapy with PEG-IFN plus RBV was effective, especially in genotype 2/3. Uric acid might be useful as a predictive factor for response to therapy for chronic hepatitis.
참고문헌 (29)
- "Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium", J Viral Hepat, 6, pp.35~47 (1999)
- Seeff LB., "Natural history of chronic hepatitis C", Hepatology, 36(5 Suppl 1), pp.S35~S46 (2002)
- Romero-Gomez M, "Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients", Gastroenterology, 128, pp.636~641 (2005)
- Poynard T, "Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C", Hepatology, 32, pp.1131~1137 (2000)
- Strader DB, "Diagnosis, management, and treatment of hepatitis C", Hepatology, 39, pp.1147~1171 (2004)
- European Association for the Study of the Liver, "EASL International Consensus Conference on hepatitis C. Paris, 26-28, February 1999, Consensus Statement", J Hepatol, 30, pp.956~961 (1999), Consensus Statement. J Hepatol
- Tsoi KK, "Endoscopy for upper gastrointestinal bleeding: how urgent is it?", Nat Rev Gastroenterol Hepatol, 6, pp.463~469 (2009)
- Hadziyannis SJ, "Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose", Ann Intern Med, 140, pp.346~355 (2004)
- McHutchison JG, "Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection", N Engl J Med, 361, pp.580~593 (2009)
- Fried MW, "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection", N Engl J Med, 347, pp.975~982 (2002)
- Manns MP, "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial", Lancet, 358, pp.958~965 (2001)
- Davis GL, "Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C", Hepatology, 38, pp.645~652 (2003)
- Ferenci P, "Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)", ribavirin, 2005, pp.43, 425~433
- Davis GL, "Factors predictive of a beneficial response to therapy of hepatitis C", Hepatology, 26(3Suppl 1), pp.122S~127S (1997)
- Ge D, "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance", Nature, 461, pp.399~401 (2009)
- Thompson AJ, "Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus", Gastroenterology, 139, pp.120~129 (2010)
- Dai CY, "Insulin resistance pre-dicts response to peginterferon-alpha", ribavirin combination therapy in chronic hepatitis C patients, 2009, pp.50, 712~718
- Hung CH, "Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications", Expert Rev Anti Infect Ther, 9, pp.525~533 (2011)
- Lopez-Suarez A, "Serum urate levels and urinary uric acid excretion in subjects with metabolic syndrome", Med Clin (Barc), 126, pp.321~324 (2006)
- Puoti C, "HCV carriers with persistently normal aminotransferase levels", Hepatology, 40, pp.266~267 (2004)
- Cavalcante LN, "Predictive factors associated with hepatitis C antiviral therapy response", World J Hepatol, 7, pp.1617~1631 (2015)
- Pellicano R, "Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection?", J Med Virol, 80, pp.628~631 (2008)
- Civantos Modino S, "Hyperuricemia and metabolic syndrome in children with overweight and obesity", Endocrinol Nutr, 59, pp.533~538 (2012)
- Abreu E, "Association between hyperuricemia and insulin resistance", Acta Med Port, 24(Suppl 2), pp.565~574 (2011)
- Miyanari Y, "The lipid droplet is an important organelle for hepatitis C virus production", Nat Cell Biol, 9, pp.1089~1097 (2007)
- Lanaspa MA, "Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver", J Biol Chem, 287, pp.40732~40744 (2012)
- Choi YJ, "Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes", Lab Invest, 94, pp.1114~1125 (2014)
- Zhu Y, "High uric acid directly inhibits insulin signalling and induces insulin resistance", Biochem Biophys Res Commun, 447, pp.707~714 (2014)
- Szanto P, "Steatosis in hepatitis C virus infection: response to anti-viral therapy", J Gastrointestin Liver Dis, 15, pp.117~124 (2006)